Hugo Sigman and his wife, Silvia Gold, lead Grupo Insud, a conglomerate of companies linked to the pharmaceutical, agribusiness and cultural sectors, among others. Among the firms that make up this group is mAbxience, which since 2009 has specialized in the research and development of monoclonal antibodies. In 2022 it announced the sale of 55% of this company for US$540 million.
